Breckenridge Pharmaceutical Initiates Class II Recall of Duloxetine Due to N-Nitroso-Duloxetine Impurity
Breckenridge Pharmaceutical, Inc. has initiated a Class II recall (D-0522-2026) for 165,761 bottles of Duloxetine Delayed-Release Capsules USP, 60mg. The recall, stemming from CGMP deviations at manufacturer Towa Pharmaceutical Europe S.L., cites N-nitroso-duloxetine impurity exceeding FDA limits. This event signals critical supply chain vulnerabilities and heightened regulatory scrutiny on nitrosamine control for procurement and regulatory teams.
Critical Recall of Duloxetine by Breckenridge Pharmaceutical Due to Nitrosamine Impurity
Breckenridge Pharmaceutical, Inc., based in Berkeley Heights, NJ, has initiated a voluntary Class II recall, identified as D-0522-2026, for a significant volume of Duloxetine Delayed-Release Capsules USP, 60mg. This recall, formally initiated on April 21, 2026, and classified by the FDA on May 6, 2026, directly impacts the supply chain for this widely prescribed antidepressant and pain management medication. The primary reasons cited are Current Good Manufacturing Practice (CGMP) deviations and, critically, the presence of N-nitroso-duloxetine impurity at levels exceeding the FDA’s recommended limits. The specific affected product is NDC 51991-748-90, from lot 241069C, with an expiration date of May 31, 2027. For procurement directors, this means an immediate need to secure alternative supplies for Duloxetine Hydrochloride to prevent stockouts and ensure patient access. Regulatory affairs heads must promptly review their internal quality systems and supplier agreements to mitigate similar risks, particularly concerning nitrosamine contamination, which remains a high-priority area for global regulators.
Supply Chain Disruption: Duloxetine Market Impact and Distribution
The scale of this recall presents a tangible disruption to the U.S. pharmaceutical market. Breckenridge Pharmaceutical, Inc. has recalled 165,761 90-count bottles of Duloxetine Delayed-Release Capsules USP, 60mg. This substantial quantity, distributed nationwide across the USA, represents a significant portion of the available supply for this specific dosage and packaging. Supply chain VPs must assess their current inventory levels and the potential for regional shortages, initiating contingency plans to source Duloxetine from unaffected manufacturers. The brand names associated with this generic, such as DULOXETINE, underscore its market relevance. Business development executives should monitor market dynamics closely, as this event could create opportunities for competitors with robust supply chains and compliant manufacturing processes to capture market share. The recall's 'Ongoing' status signifies continued market uncertainty until remediation is complete and alternative supplies are firmly established.
Unpacking the Manufacturing Origin: Towa Pharmaceutical Europe S.L.'s Role
A critical detail for decision-makers is the manufacturing origin of the recalled product. While Breckenridge Pharmaceutical, Inc. is the recalling distributor, the Duloxetine Delayed-Release Capsules USP, 60mg, were manufactured by Towa Pharmaceutical Europe S.L., located in Martorelles, Barcelona, Spain. This distinction is vital for procurement and regulatory teams. The CGMP deviations and the N-nitroso-duloxetine impurity issue likely originate at Towa Pharmaceutical Europe S.L.'s facility, placing the Spanish manufacturer under indirect but significant FDA scrutiny. Companies currently sourcing APIs or finished drug products from Towa Pharmaceutical Europe S.L., or those evaluating them as potential suppliers, must immediately reassess their due diligence and supplier qualification frameworks. This incident underscores the imperative for stringent oversight of contract manufacturing organizations (CMOs) and robust audit programs to ensure compliance with international quality standards, regardless of the distributor's location.
Escalating Nitrosamine Concerns: A Broader Industry Challenge
The detection of N-nitroso-duloxetine impurity above FDA recommended limits is not an isolated event but rather indicative of a persistent and escalating industry-wide challenge concerning nitrosamine contamination in pharmaceutical products. Regulatory bodies globally, including the FDA, have intensified their focus on these genotoxic impurities following a series of recalls involving various drug classes. This specific impurity in Duloxetine Hydrochloride reinforces the need for pharmaceutical manufacturers and distributors to implement comprehensive nitrosamine risk assessments, robust control strategies, and validated analytical testing methods throughout their supply chains. Regulatory affairs heads must ensure their organizations are fully compliant with evolving FDA guidance on nitrosamines, proactively identifying potential sources of impurity formation, from raw material sourcing to finished product storage. Failure to address this systemic issue can lead to costly recalls, significant reputational damage, and prolonged regulatory actions, impacting market access and profitability.
Regulatory Outlook and Remediation for Breckenridge and Towa
With the recall status listed as 'Ongoing,' Breckenridge Pharmaceutical, Inc. is actively managing the withdrawal of affected Duloxetine stock from the U.S. market. The FDA will expect a thorough and timely investigation into the root cause of the CGMP deviations and the N-nitroso-duloxetine impurity at Towa Pharmaceutical Europe S.L. and the implementation of comprehensive corrective and preventive actions (CAPA). Regulatory affairs teams at Breckenridge must demonstrate effective oversight of their contract manufacturer and ensure all deficiencies are addressed to prevent recurrence. This event could trigger further FDA inspections of both Breckenridge and Towa Pharmaceutical Europe S.L. and potentially lead to more severe regulatory actions if remediation efforts are deemed inadequate. Business development executives should be aware that such regulatory issues can impact future product approvals, partnership opportunities, and overall market confidence in both the distributor and the manufacturer, emphasizing the need for robust quality and compliance frameworks.